ARTICLE
25 March 2013

The New Biocidal Products Regulation: Last Chance To Influence Regulatory Framework Before It Bites!

SJ
Steptoe LLP
Contributor
In more than 100 years of practice, Steptoe has earned an international reputation for vigorous representation of clients before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and professional staff across the US, Europe and Asia.
At last week’s Steptoe seminar on the new Biocidal Products Regulation, No 528/2012, the European Commission confirmed its intention to seek accelerated agreement on a legislative amendment to the BPR.
European Union Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

At last week's Steptoe seminar on the new Biocidal Products Regulation, (EU) No 528/2012 (BPR), the European Commission confirmed its intention to seek accelerated agreement on a legislative amendment to the BPR.  If prompt consensus can be reached with the Council and the European Parliament, the changes will take effect before the new regime becomes applicable on 1 September 2013.  As with REACH, the new biocides regime is relevant not only to manufacturers and formulators of biocides, but downstream users as well.

In our assessment, although the proposed changes are being presented as clarifications and corrections, in fact they would significantly affect the biocidal supply chain.  For example, mandatory sharing would be extended to all data on existing active substances.  However, the Commission did express a willingness to accept input on its new proposals during a brief window.

Steptoe's seminar brought together both regulators and commercial actors at all stages of the supply chain to provide a comprehensive overview of important issues under the BPR. 

To learn more about the impact on your business, please click here to view all of the presentations from the event.
 
We would be happy to discuss any questions regarding:

  • Issues covered during the seminar
  • Opportunities for advocacy to shape the forthcoming BPR amendments
  • Particular commercial and regulatory challenges that your business may face

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
25 March 2013

The New Biocidal Products Regulation: Last Chance To Influence Regulatory Framework Before It Bites!

European Union Food, Drugs, Healthcare, Life Sciences
Contributor
In more than 100 years of practice, Steptoe has earned an international reputation for vigorous representation of clients before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and professional staff across the US, Europe and Asia.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More